Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16971418 | 0.82 | F11 (0.40) | — | |
| SCHEMBL16971967 | 0.81 | GABRA2 (0.37) | GABRA2GABRB2AR | |
| SCHEMBL16972255 | 0.80 | NOTUM (0.36) | GABRA2GABRB2AR | |
| SCHEMBL16971754 | 0.79 | GABRA2 (0.31) | GABRA2GABRB2AR | |
| SCHEMBL16971566 | 0.79 | GABRA2 (0.36) | GABRA2GABRB2AR | |
| SCHEMBL16971662 | 0.76 | GABRA2 (0.34) | GABRA2GABRB2AR | |
| SCHEMBL17644828 | 0.75 | KMO (0.36) | AR | |
| SCHEMBL16972246 | 0.74 | KMO (0.34) | AR | |
| SCHEMBL16971719 | 0.74 | CFTR (0.33) | AR | |
| SCHEMBL16971339 | 0.73 | AR (0.33) | GABRA2GABRB2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| CN-116987080-A | Macrocyclic compounds with heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-110845498-B | Macrocyclic compounds having heterocyclic P2' groups as factor XIA inhibitors | 百时美施贵宝公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-20 | — | — | US | disclosed |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3392249-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
| EP-3099687-B1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-22 | — | — | US | disclosed |
| EP-3099687-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9453018-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-07 | — | — | US | disclosed |
| WO-2015116886-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053247-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F11 | GABRA2 2845/4885GABRB2 3413/4885AR 3455/4885 |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | GABRA2 2663/4885GABRB2 3270/4885AR 3402/4885 |
| US-20180186795-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | GABRA2 2663/4885GABRB2 3270/4885AR 3402/4885 |
| US-20200055854-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | GABRA2 2845/4885GABRB2 3413/4885AR 3455/4885 |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | GABRA2 2663/4885GABRB2 3270/4885AR 3402/4885 |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI2, F2, TFPI | GABRA2 3386/4885GABRB2 3827/4885AR 4229/4885 |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | GABRA2 2663/4885GABRB2 3270/4885AR 3402/4885 |
| US-10336754-B2 | Pyrimidinones as factor XIa inhibitors | TFPI, TFPI2, F2 | GABRA2 2663/4885GABRB2 3270/4885AR 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.